RU2579511C2 - Производные фуро[3,2-в]пирана, применимые в синтезе аналогов - Google Patents

Производные фуро[3,2-в]пирана, применимые в синтезе аналогов Download PDF

Info

Publication number
RU2579511C2
RU2579511C2 RU2012136468/04A RU2012136468A RU2579511C2 RU 2579511 C2 RU2579511 C2 RU 2579511C2 RU 2012136468/04 A RU2012136468/04 A RU 2012136468/04A RU 2012136468 A RU2012136468 A RU 2012136468A RU 2579511 C2 RU2579511 C2 RU 2579511C2
Authority
RU
Russia
Prior art keywords
compound
hydroxyl
alkyl
group
oxygen atom
Prior art date
Application number
RU2012136468/04A
Other languages
English (en)
Russian (ru)
Other versions
RU2012136468A (ru
Inventor
Ацуси ЭНДО
Чарлз И. ЧЕЙЗ
Фрэнсис Дж. ФАН
Original Assignee
Эйсай Ар Энд Ди Менеджмент Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эйсай Ар Энд Ди Менеджмент Ко., Лтд. filed Critical Эйсай Ар Энд Ди Менеджмент Ко., Лтд.
Publication of RU2012136468A publication Critical patent/RU2012136468A/ru
Application granted granted Critical
Publication of RU2579511C2 publication Critical patent/RU2579511C2/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02Silicon compounds
    • C07F7/08Compounds having one or more C—Si linkages
    • C07F7/18Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804Compounds having Si-O-C linkages
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/10Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/12Radicals substituted by oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D407/00Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/06Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04Ortho-condensed systems
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
RU2012136468/04A 2010-01-26 2011-01-26 Производные фуро[3,2-в]пирана, применимые в синтезе аналогов RU2579511C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29833710P 2010-01-26 2010-01-26
US61/298,337 2010-01-26
PCT/US2011/022611 WO2011094339A1 (en) 2010-01-26 2011-01-26 Furo [3, 2 -b] pyrane derivatives useful in the synthesis of halichondrin b analogs

Publications (2)

Publication Number Publication Date
RU2012136468A RU2012136468A (ru) 2014-03-10
RU2579511C2 true RU2579511C2 (ru) 2016-04-10

Family

ID=43726543

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2012136468/04A RU2579511C2 (ru) 2010-01-26 2011-01-26 Производные фуро[3,2-в]пирана, применимые в синтезе аналогов

Country Status (11)

Country Link
US (6) US8203010B2 (OSRAM)
EP (1) EP2528914B1 (OSRAM)
JP (1) JP5800834B2 (OSRAM)
CN (1) CN102803254B (OSRAM)
BR (1) BR112012018232B8 (OSRAM)
CA (1) CA2787919C (OSRAM)
IL (1) IL220913A (OSRAM)
MX (1) MX2012008510A (OSRAM)
RU (1) RU2579511C2 (OSRAM)
SG (2) SG182612A1 (OSRAM)
WO (1) WO2011094339A1 (OSRAM)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1087960T3 (da) * 1998-06-17 2011-06-14 Eisai R&D Man Co Ltd Makrocykliske analoger og fremgangsmåder til deres anvendelse og fremstilling
HUE046436T2 (hu) 2004-06-03 2020-02-28 Eisai R&D Man Co Ltd Köztitermékek halikondrin B elõállításához
US8093410B2 (en) 2007-10-03 2012-01-10 Eisai R&D Management Co., Ltd. Intermediates and methods for the synthesis of halichondrin B analogs
CA2720632C (en) * 2008-04-04 2016-12-20 Eisai R&D Management Co., Ltd. Halichondrin b analogs
MA33127B1 (fr) 2009-03-30 2012-03-01 Eisai R&D Man Co Ltd Composition liposomique
RU2579511C2 (ru) 2010-01-26 2016-04-10 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Производные фуро[3,2-в]пирана, применимые в синтезе аналогов
TWI559778B (zh) 2011-09-18 2016-11-21 觸控調諧音樂公司 具有卡拉ok及/或照相亭特徵的數位點唱機裝置以及與其相關聯的方法
RU2689977C2 (ru) 2012-12-04 2019-05-30 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Применение эрибулина для лечения рака молочной железы
JP6404242B2 (ja) 2013-06-26 2018-10-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 がんの治療のための併用療法としてのエリブリンおよびレンバチニブの使用
US9850254B2 (en) 2013-07-03 2017-12-26 Sandoz Ag Synthetic process for preparation of macrocyclic C1-keto analogs of Halichondrin B and intermediates useful therein including intermediates containing-SO2-(p-tolyl) groups
CN103483352A (zh) * 2013-10-18 2014-01-01 李友香 抗肿瘤的药用原料药
EP3689881B1 (en) * 2013-11-04 2022-01-12 Eisai R&D Management Co., Ltd. Macrocyclization reactions and intermediates useful in the synthesis of analogs of halichondrin b
SG10201805024YA (en) 2013-12-06 2018-07-30 Eisai R&D Man Co Ltd Methods useful in the synthesis of halichondrin b analogs
EP3148526B1 (en) 2014-05-28 2021-01-06 Eisai R&D Management Co., Ltd. Use of eribulin in the treatment of cancer
EP3160970A4 (en) 2014-06-30 2017-12-27 President and Fellows of Harvard College Synthesis of halichondrin analogs and uses thereof
EP3265122B1 (en) 2015-03-04 2022-05-04 Merck Sharp & Dohme Corp. Combination of pembrolizumab and eribulin for treating triple-negative breast cancer
CA2978226C (en) 2015-03-04 2025-02-18 Eisai R&D Management Co., Ltd. COMBINATION OF A PD-1 ANTAGONIST AND A VEGFR/FGFR/RET TYROSINE KINASE INHIBITOR TO TREAT CANCER
US10344038B2 (en) 2015-04-30 2019-07-09 President And Fellows Of Harvard College Chromium-mediated coupling and application to the synthesis of halichondrins
RU2020141025A (ru) 2015-05-07 2020-12-28 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Реакции макроциклизации и промежуточные соединения и другие фрагменты, полезные в синтезе макролидов галихондринов
US10676481B2 (en) 2016-02-12 2020-06-09 Eisai R&D Management Co., Ltd. Intermediates in the synthesis of eribulin and related methods of synthesis
PE20181953A1 (es) 2016-03-02 2018-12-17 Eisai Randd Man Co Ltd Conjugados de anticuerpo y farmaco basados en eribulina y metodos para su uso
US12029724B2 (en) 2016-04-28 2024-07-09 Eisai R&D Management Co., Ltd. Method for inhibiting tumor growth
KR102404629B1 (ko) 2016-06-30 2022-06-02 에자이 알앤드디 매니지먼트 가부시키가이샤 할리콘드린 마크롤리드 및 그의 유사체의 합성에 유용한 프린스 반응 및 중간체
CN110072552A (zh) 2016-10-14 2019-07-30 默沙东公司 用于治疗尿路上皮癌的pd-1拮抗剂和艾立布林的组合
JP6978758B2 (ja) 2016-11-11 2021-12-08 プレジデント アンド フェローズ オブ ハーバード カレッジ パラジウム媒介ケトール化
CN108658956B (zh) * 2017-03-28 2021-02-02 上海时莱生物技术有限公司 艾日布林中间体及其制备方法
US9938288B1 (en) 2017-04-05 2018-04-10 President And Fellows Of Harvard College Macrocyclic compound and uses thereof
JP7168580B2 (ja) 2017-04-05 2022-11-09 プレジデント アンド フェローズ オブ ハーバード カレッジ 大環状化合物およびその使用
CN108948064B (zh) * 2017-05-17 2021-02-02 上海时莱生物技术有限公司 一种艾日布林中间体及其制备方法
BR112020000141A2 (pt) 2017-07-06 2020-07-14 President And Fellows Of Harvard College síntese de halicondrinas
US11498892B2 (en) 2017-07-06 2022-11-15 President And Fellows Of Harvard College Fe/Cu-mediated ketone synthesis
US20190046513A1 (en) 2017-08-10 2019-02-14 Huya Bioscience International, Llc Combination therapies of hdac inhibitors and tubulin inhibitors
WO2019099646A1 (en) 2017-11-15 2019-05-23 President And Fellows Of Harvard College Macrocyclic compounds and uses thereof
WO2019097073A1 (en) 2017-11-20 2019-05-23 Basilea Pharmaceutica International AG Pharmaceutical combinations for use in the treatment of neoplastic diseases
US11542269B2 (en) 2018-01-03 2023-01-03 Eisai R&D Management Co., Ltd. Prins reaction and compounds useful in the synthesis of halichondrin macrolides and analogs thereof
US12036204B2 (en) 2019-07-26 2024-07-16 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumor
US11083705B2 (en) 2019-07-26 2021-08-10 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumor

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU652180A1 (ru) * 1975-12-16 1979-03-15 Краснодарский политехнический институт 1(Фурил-2,)-2-(2-,, формилфурил-5,, ) этилен или его метильное производное как промежуточный продукт дл синтеза фуран-2,5-дикарбоновой кислоты и способ его получени
WO1993017690A1 (en) * 1992-03-12 1993-09-16 President And Fellows Of Harvard College Halichondrins and related compounds
WO2005118565A1 (en) * 2004-06-03 2005-12-15 Eisai Co., Ltd. Intermediates for the preparation of halichondrin b

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5436238A (en) * 1992-03-12 1995-07-25 President And Fellows Of Harvard College Halichondrins and related compounds
GB9206244D0 (en) 1992-03-23 1992-05-06 Pharma Mar Sa Cytotoxic compound from a marine sponge
TW255880B (OSRAM) 1992-09-09 1995-09-01 Hoechst Ag
US6194586B1 (en) 1996-09-06 2001-02-27 Eli Lilly And Company Selective sulphonation of the primary alcohol of a diol containing both primary and secondary alcohols
DK1087960T3 (da) * 1998-06-17 2011-06-14 Eisai R&D Man Co Ltd Makrocykliske analoger og fremgangsmåder til deres anvendelse og fremstilling
US6653341B1 (en) * 1998-06-17 2003-11-25 Eisai Co., Ltd. Methods and compositions for use in treating cancer
US8097648B2 (en) 1998-06-17 2012-01-17 Eisai R&D Management Co., Ltd. Methods and compositions for use in treating cancer
CA2822994C (en) * 2004-06-03 2016-09-27 Eisai R&D Management Co., Ltd. Intermediates for the preparation of analogs of halichondrin b
US20060045846A1 (en) 2004-08-30 2006-03-02 Horstmann Thomas E Reagents and methods for labeling terminal olefins
JP2008522623A (ja) 2004-12-09 2008-07-03 エーザイ株式会社 ハリコンドリンbアナログを使用した癌治療でのチューブリンアイソタイプのスクリーニング
WO2008010776A1 (en) 2006-07-21 2008-01-24 Agency For Science, Technology And Research Aigialomycin d and derivatives thereof and their use in treating cancer or malaria or a microbial infection
US8093410B2 (en) 2007-10-03 2012-01-10 Eisai R&D Management Co., Ltd. Intermediates and methods for the synthesis of halichondrin B analogs
WO2009064029A1 (en) 2007-11-16 2009-05-22 Eisai R & D Management Co., Ltd. Novel intermediate for halichondrin b analog synthesis and novel desulfonylation reaction used for the intermediate
CA2720632C (en) * 2008-04-04 2016-12-20 Eisai R&D Management Co., Ltd. Halichondrin b analogs
RU2579511C2 (ru) 2010-01-26 2016-04-10 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Производные фуро[3,2-в]пирана, применимые в синтезе аналогов
WO2012147900A1 (en) 2011-04-28 2012-11-01 Eisai R&D Management Co., Ltd. Microreactor process for halichondrin b analog synthesis
AU2012344697A1 (en) 2011-11-30 2014-07-10 Alphora Research Inc. Process for preparation of (3R)-2,4-di-leaving group-3-methylbut-1-ene
US9278979B2 (en) 2012-03-30 2016-03-08 Alphora Research Inc. Synthetic process for preparation of macrocyclic C1-keto analogs of halichondrin B and intermediates useful therein
US9850254B2 (en) 2013-07-03 2017-12-26 Sandoz Ag Synthetic process for preparation of macrocyclic C1-keto analogs of Halichondrin B and intermediates useful therein including intermediates containing-SO2-(p-tolyl) groups
EP3689881B1 (en) 2013-11-04 2022-01-12 Eisai R&D Management Co., Ltd. Macrocyclization reactions and intermediates useful in the synthesis of analogs of halichondrin b
SG10201805024YA (en) 2013-12-06 2018-07-30 Eisai R&D Man Co Ltd Methods useful in the synthesis of halichondrin b analogs
RU2020141025A (ru) 2015-05-07 2020-12-28 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Реакции макроциклизации и промежуточные соединения и другие фрагменты, полезные в синтезе макролидов галихондринов
US10676481B2 (en) 2016-02-12 2020-06-09 Eisai R&D Management Co., Ltd. Intermediates in the synthesis of eribulin and related methods of synthesis
KR102404629B1 (ko) 2016-06-30 2022-06-02 에자이 알앤드디 매니지먼트 가부시키가이샤 할리콘드린 마크롤리드 및 그의 유사체의 합성에 유용한 프린스 반응 및 중간체

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU652180A1 (ru) * 1975-12-16 1979-03-15 Краснодарский политехнический институт 1(Фурил-2,)-2-(2-,, формилфурил-5,, ) этилен или его метильное производное как промежуточный продукт дл синтеза фуран-2,5-дикарбоновой кислоты и способ его получени
WO1993017690A1 (en) * 1992-03-12 1993-09-16 President And Fellows Of Harvard College Halichondrins and related compounds
WO2005118565A1 (en) * 2004-06-03 2005-12-15 Eisai Co., Ltd. Intermediates for the preparation of halichondrin b

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Dae-Shik Kim et al, JACS,2009,v.131,no.43,p.15636-15641. *
Kiyoshi Horita et at, Tetrahed letters,1997,v.38,no.52,p.8965-8968. *

Also Published As

Publication number Publication date
US8927597B2 (en) 2015-01-06
US20130123519A1 (en) 2013-05-16
IL220913A (en) 2016-11-30
US20110184190A1 (en) 2011-07-28
BR112012018232A2 (pt) 2016-02-23
MX2012008510A (es) 2012-11-21
SG182612A1 (en) 2012-08-30
EP2528914B1 (en) 2014-06-11
JP5800834B2 (ja) 2015-10-28
US8203010B2 (en) 2012-06-19
US10494388B2 (en) 2019-12-03
US20120289718A1 (en) 2012-11-15
US20180162885A1 (en) 2018-06-14
SG10201500552PA (en) 2015-03-30
BR112012018232B8 (pt) 2023-01-10
US9382262B2 (en) 2016-07-05
WO2011094339A1 (en) 2011-08-04
BR112012018232B1 (pt) 2022-11-29
RU2012136468A (ru) 2014-03-10
JP2013518116A (ja) 2013-05-20
US20160376294A1 (en) 2016-12-29
US20150175620A1 (en) 2015-06-25
US8350067B2 (en) 2013-01-08
CA2787919A1 (en) 2011-08-04
CA2787919C (en) 2018-07-31
EP2528914A1 (en) 2012-12-05
US9856276B2 (en) 2018-01-02
CN102803254A (zh) 2012-11-28
CN102803254B (zh) 2016-09-14

Similar Documents

Publication Publication Date Title
RU2579511C2 (ru) Производные фуро[3,2-в]пирана, применимые в синтезе аналогов
CA3028453C (en) Intermediates for the preparation of analogs of halichondrin b
CN105916861B (zh) 可用于合成软海绵素b类似物的方法
JP5544553B2 (ja) ピリピロペン誘導体の製造法およびその製造中間体
JP2000109497A (ja) スピロ環式c―グリコシド
ES2341528B1 (es) Nuevo metodo estereoespecifico para la p areparacion de compuestos denitrato de dioxabiciclooctano.
JP7116384B2 (ja) 高収率の血管漏出遮断薬の調製方法
EP2149577B1 (en) New stereospecific method for the preparation of dioxa-bicyclooctane compounds
JP4170799B2 (ja) 抗腫瘍活性物質エクチナサイジン743の改良合成法
JP5265144B2 (ja) 3−o−置換−カテキン類誘導体の新規製造方法
JP2010270145A (ja) 14位で官能化されたタキサン誘導体及びその製造方法
CZ306366B6 (cs) Způsob přípravy intermediátu přípravy prostaglandinového derivátu alfaprostolu
WO2010055138A1 (en) New stereospecific method for the preparation of dioxa-bicyclooctane compounds
CN103172654A (zh) 紫杉烷类化合物及其制备方法

Legal Events

Date Code Title Description
HC9A Changing information about inventors